Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Androgen influence on exocrine pancreatic cancer


Since the discovery of the first gastrointestinal hormones it has been intriguing to think that these defined chemical messengers may also influence the growth of tumors. Today, treatment with sex-hormones is well documented—and used in clinical practice—in prostatic (1,2), breast (3), endo-metrial, and ovarian carcinoma(4). Hormonal therapy (progesterone) has also been tried with some success in renal carcinoma(5,6). Nevertheless, cancers of the gastrointestinal tract—colorectal, liver, stomach, and pancreatic carcinoma, which constitute 25 percent of all malignancies in Scandinavia—are only treated by other means, mainly surgery, although there is substantial evidence today that these tumors can also be influenced by hormones.

This is a preview of subscription content, log in to check access.


  1. 1

    Torti FM. Hormonal therapy for prostate cancer. New Engl. J. Med. 1984; 311: 1313- 1318.

  2. 2

    Waxman J. Hormonal aspects of prostatic cancer: A review. J. Royal Soc. Med. 1985; 78: 129–1316.

  3. 3

    Hubay CA, Arafah B, Gordon NH, Guyton SP, Crowe JP. Hormone receptors. An update and application. Surg. Clin. North Am. 1984; 64: 1155–1168.

  4. 4

    Kauppila A. Protestin therapy of endometrial, breast and ovarial carcinoma. A review of clinical observations. Acta Obstet. Gynecol. Scand. 1984; 63: 441–448.

  5. 5

    Mukamel E, Bruhis S, Nissenkorn I, Servadio C. Steroid receptors in renal cell carcinoma: Relevance to hormonal therapy. J. Urol. 1984; 131: 227–233.

  6. 6

    Nakano E, Tada Y, Fujioka H, Matsuda M, Osafune M, Kotake T, Sato B, Takaha M, Soneda T. Hormone receptor in renal cell carcinoma and correlation with clinical response to endocrine therapy. J. Urol. 1984; 132: 240–246.

  7. 7

    Grieg RG, Schein PS. Therapy of gastrointestinal cancer, In: Polak, Bloom, Wright, Butler (Eds.), Basic science in gastroenterology. Diseases of the gut, United Kingdoms: Glaxo group research limited. Hearts, 1986: 329–336.

  8. 8

    Sandberg AA, Rosenthal HE. Steroid receptors in exocrine glands: the pancreas and the prostate, J. Steroid Biochem. 1979; 11: 293–299.

  9. 9

    Sandberg AA, Kirdany RY, Varkarakis MJ, Murphy GP. Estrogen receptor protein in pancreas. Steroids 1973; 22: 259–271.

  10. 10

    Rosenthal HE, Sandberg AA. Estrogen binding proteins in rat pancreas. J. Steroid Biochem. 1978; 9: 1133–1139.

  11. 11

    Andrén-Sandberg Å. Estrogens and pancreatic cancer. Some recent aspects. Scand. J. Gastroenterol. 1986; 21: 129–135.

  12. 12

    Greenway BA. Carcinoma of the exocrine pancreas: A sex hormone responsive tumour? Br. J. Surg. 1987; 74: 441–442.

  13. 13

    Boctor AM, Band P, and Grossman A. Requirement for an accessory factor for binding of (3H)estradiol to protein to the cytosol fraction of rat pancreas. Proc. Natl. Acad. Sci. USA 1981; 78: 5648–5652.

  14. 14

    Band P, Richardson SB, Boctor AM, Grossman A. Somatostatin enhances binding of (3H)estradiol to a cytosolic protein in rat pancreas. Possible role of oligopeptide coligands in secretions. J. Biol. Chem. 1983; 258: 7284–7287.

  15. 15

    Pousette Å. Demonstration of an androgen receptor in rat pancreas. Biochem. J. 1976; 157: 229–234.

  16. 16

    Lhoste EF, Roebuck BD, Stern JE, Longnecker DS. Effect of orchiectomy and testosterone on the early stages of azaserine-induced pancreatic carcinogenesis in the rat. Pancreas 1987; 2: 38–43.

  17. 17

    Greenway B, Iqbal MJ, Johnson PJ, Williams R. Low serum testosterone concentrations in patients with carcinoma of the pancreas. Br. Med. J. 1983; 286: 93–95.

  18. 18

    Militello C, Sperti C, Foresta C. Plasma levels of testosterone and hypophyseal gonadotropins in men affected by pancreatic cancer. Digestion 1984; 30: 122.

  19. 19

    Shearer MG, Taggart D, Gray C, Imrie CW. Useful differentiation between pancreatic carcinoma and chronic pancreatitis by testosterone assay. Digestion 1984; 30: 106.

  20. 20

    Gonzalez-Barcena D, Rangel-Garcia NE, Perez-Sanchez PL, Guttierrez-Damperio C, Garcia-Carrasco F, Comaru-Schally AM, Schally AV. Response to D-TRP-6 LH-RH in advanced adenocarcinoma of pancreas. Lancet 1986; ii (8499): 154.

  21. 21

    Schally AV, Comaru-Schally AM, Redding TW. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc. Soc. Exp. Biol. Med. 1984; 175: 259–281.

  22. 22

    Pasquali C, Marra S, Scandellari C, Pedrazzoli P. Testosterone and hypophyseal gonadotropin plasma levels in men affected by pancreatic cancer. Ital. J. Gastroenterol. 1985; 17: 56.

  23. 23

    Greenway B, Iqbal MJ, Johnson PJ, Williams R. Serum sex-steroid concentrations in patients with pancreatic carcinoma. Br. J. Surg. 1982; 69: 293–296.

  24. 24

    Robles-Diaz G, Diaz V, Ornelas R, Mendez JP, Wolpert E. Testosterone:Dihydrotestosterone ratio, a new tumor marker in pancreatic cancer. Dig. Dis. Sci. 1986; 31: 68S.

  25. 25

    Greenway B, Duke D, Pym B. A control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. Br. J. Surg. 1982; 69: 595–000.

  26. 26

    Longnecker DS. The azaserine-induced model of pancreatic carcinogenesis in rats. In: Scarpelli DG, Reddy JK, Longnecher DS, Eds., Experimental pancreatic carcinogenesis. Boca Raton, CRC Press Inc., 1986: 117–130.

  27. 27

    Lhoste EF, Roebuck BD, Brinck-Johnsen T, Longnecker DS. Effect of castration and hormone replacement on azaserine-induced pancreatic carcinogenesis in male and female Ficher rats. Carcinogenesis 1987; 8: 699–703.

  28. 28

    Hayashi Y, Katayama H. Promoting effect of testosterone propionate on experimental exocrine pancreatic tumors by 4-Hydroxyaminoquinoline-l-oxide in rats. Toxicol. Lett. 1981; 9: 349–356.

  29. 29

    Benz C, Hollander C, Miller B. Endocrine-responsive pancreatic carcinoma: steroid binding and cytotoxicity studies in human tumor cell lines. Cancer Res. 1986; 46: 2276–2281.

  30. 30

    Redding TW, Schally AV. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc. Natl. Acad. Sci. USA 1984; 81, 248–252.

  31. 31

    Paz-Bouza JI, Redding TW, Schally AV. Treatment of nitrosamine-induced pancreatic tumors in hamsters with analoges of somatostatine and luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA 1987; 84, 1112–1116.

Download references

Author information

Correspondence to Å Andrén-Sandberg.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Andrén-Sandberg, Å. Androgen influence on exocrine pancreatic cancer. Int J Pancreatol. 4, 363–369 (1989). https://doi.org/10.1007/BF02938472

Download citation

Key Words

  • Hormones
  • pancreas cancer